Generic Fycompa Availability

Fycompa is a brand name of perampanel, approved by the FDA in the following formulation(s):

FYCOMPA (perampanel - suspension;oral)

• Manufacturer: EISAI INC
  Approval date: April 29, 2016
  Strength(s): 0.5MG/ML ^[RLD]

FYCOMPA (perampanel - tablet;oral)

• Manufacturer: EISAI INC
  Approval date: October 22, 2012
  Strength(s): 2MG ^[RLD], 4MG ^[RLD], 6MG ^[RLD], 8MG ^[RLD], 10MG ^[RLD], 12MG ^[RLD]

Has a generic version of Fycompa been approved?

No. There is currently no therapeutically equivalent version of Fycompa available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fycompa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
  Patent 6,949,571
  Issued: September 27, 2005
  Inventor(s): Nagato; Satoshi & Ueno; Kohshi & Kawano; Koki & Norimine; Yoshihiko & Ito; Koichi & Hanada; Takahisa & Ueno; Masataka & Amino; Hiroyuki & Ogo; Makoto & Hatakeyama; Shinji & Groom; Anthony John & Rivers; Leanne & Smith; Terence
  Assignee(s): Eisai Co., Ltd.
  The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. In the formula, Q indicates NH, O or S; and R1, R2, R3, R4 and R5 are the same as or different from each other and each indicates hydrogen atom, a halogen atom, a C1-6 alkyl group or a group represented by the formula —X-A (wherein X indicates a single bond, an optionally substituted C1-6 alkylene group etc.; and A indicates an optionally substituted C6-14 aromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.).
  
  Patent expiration dates:
  • June 8, 2021
    
    ✓ 
    Patent use: TREATMENT OF EPILEPSY
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Method for producing 1, 2-dihydropyridine-2-one compound
  Patent 8,772,497
  Issued: July 8, 2014
  Assignee(s): Eisai R&D Management Co., Ltd.
  The present inventions provide a method for commercially producing a 1,2-dihydropyridine-2-one compound represented by the following formula (III-a) wherein the ring A represents an optionally substituted 2-pyridyl group, the ring B represents an optionally substituted phenyl group, and the ring C represents an optionally substituted phenyl group. Further, the invention provides crystals of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one and production processes therefore.
  
  Patent expiration dates:
  • May 16, 2026
    
    ✓ 
    Drug substance

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 22, 2017 - NEW CHEMICAL ENTITY
  • June 19, 2018 - ADJUNCTIVE THERAPY FOR THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC (PG TC) SEIZURES IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE OR OLDER.